

Phase I trial: CA47303

Submission date 08/04/2025	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 10/04/2025	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 10/04/2025	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Dr Nadine Abdullah

ORCID ID

<https://orcid.org/0000-0001-7772-7724>

Contact details

22-24 Lisburn Road

Belfast

United Kingdom

BT9 6AD

+44 2890 554040

nadine.abdullah@celerion.com

Additional identifiers

Integrated Research Application System (IRAS)

1011728

Protocol serial number

CA47303

Study information

Scientific Title

Phase I trial: CA47303

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

1. approved 02/04/2025, East of England - Cambridge East Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, United Kingdom; +44 207 104 8096; cambridgeeast.rec@hra.nhs.uk), ref: IRAS ID 1011728

2. approved 02/04/2025, MHRA (10 South Colonnade, Canary Wharf, London, E14 4PU, United Kingdom; +44 2030806000; info@mhra.gov.uk), ref: IRAS ID 1011728

Study design

Relative Bioavailability study in 20 healthy adult female volunteers

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Healthy volunteers

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

14/05/2025

Eligibility

Key inclusion criteria

Healthy human volunteer

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

45 years

Sex

Female

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

16/04/2025

Date of final enrolment

18/04/2025

Locations

Countries of recruitment

United Kingdom

Northern Ireland

Study participating centre

Celerion GB Ltd
22-24 Lisburn Road
Belfast
United Kingdom
BT9 6AD

Sponsor information

Organisation

Millicent Puerto Rico LLC

Funder(s)

Funder type

Industry

Funder Name

Millicent Puerto Rico LLC

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available